Can lithium be used in the setting of clozapine commencement in patients with COVID-19 associated neutropenia: A case report

Jin Quan Eugene Tan; Jessica L Dawson; Tarun Bastiampillai

doi:10.1002/ccr3.8758

Can lithium be used in the setting of clozapine commencement in patients with COVID-19 associated neutropenia: A case report

Clin Case Rep. 2024 Apr 12;12(4):e8758. doi: 10.1002/ccr3.8758. eCollection 2024 Apr.

Authors

Jin Quan Eugene Tan^{1

2}, Jessica L Dawson^{1

3}, Tarun Bastiampillai^{4

5}

Affiliations

¹ SA Pharmacy, Flinders Medical Centre Southern Adelaide Local Health Network Adelaide South Australia Australia.
² College of Medicine and Public Health Flinders University Adelaide South Australia Australia.
³ Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University Parkville Victoria Australia.
⁴ Discipline of Psychiatry, College of Medicine and Public Health Flinders University Adelaide South Australia Australia.
⁵ Department of Psychiatry Monash University Clayton Victoria Australia.

Abstract

COVID-19 infection may increase the likelihood of neutropenia in patients already on clozapine. In clozapine treated patients experiencing COVID-19 associated neutropenia, adjunct therapy with lithium can be considered.

Keywords: COVID‐19; antipsychotics; clozapine; neutropenia; psychiatry.

Publication types

Case Reports